Turning Point Therapeutics, EQRx Announce Clinical Collaboration To Evaluate Elzovantinib In Combination With Aumolertinib In Patients With EGFR Mutant Met-Amplified Advanced Non-Small Cell Lung Cancer
Portfolio Pulse from Benzinga Newsdesk
Turning Point Therapeutics and EQRx have announced a clinical collaboration to evaluate the combination of Elzovantinib and Aumolertinib in treating patients with EGFR mutant Met-amplified advanced non-small cell lung cancer.
October 13, 2021 | 8:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Turning Point Therapeutics is collaborating with EQRx to evaluate a new drug combination for advanced lung cancer, potentially expanding its treatment portfolio.
The collaboration with EQRx to evaluate a new treatment combination could lead to successful clinical outcomes, potentially enhancing Turning Point Therapeutics' product offerings and market position.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80